A detailed history of Twin Tree Management, LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Twin Tree Management, LP holds 323 shares of EXEL stock, worth $11,773. This represents 0.0% of its overall portfolio holdings.

Number of Shares
323
Holding current value
$11,773
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $7,093 - $8,914
323 New
323 $8,000
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $61,152 - $86,853
3,900 New
3,900 $61,000
Q2 2022

Aug 11, 2022

SELL
$17.44 - $23.16 $114,947 - $152,647
-6,591 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$17.03 - $22.67 $112,244 - $149,417
6,591 New
6,591 $149,000
Q4 2021

Feb 10, 2022

SELL
$15.84 - $21.88 $3,849 - $5,316
-243 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $3,960 - $5,137
243 New
243 $5,000
Q2 2021

Aug 12, 2021

SELL
$17.95 - $25.56 $1.32 Million - $1.89 Million
-73,769 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $932,328 - $1.15 Million
45,413 Added 160.15%
73,769 $1.67 Million
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $451,272 - $608,567
24,539 Added 642.89%
28,356 $569,000
Q3 2020

Nov 13, 2020

SELL
$20.67 - $26.94 $579,628 - $755,451
-28,042 Reduced 88.02%
3,817 $93,000
Q2 2020

Aug 12, 2020

BUY
$16.46 - $27.42 $384,011 - $639,708
23,330 Added 273.54%
31,859 $756,000
Q3 2019

Nov 12, 2019

BUY
$17.68 - $22.65 $150,792 - $193,181
8,529 New
8,529 $151,000
Q2 2019

Aug 12, 2019

SELL
$18.93 - $24.75 $375,476 - $490,916
-19,835 Closed
0 $0
Q1 2019

May 10, 2019

SELL
$19.6 - $24.76 $507,130 - $640,640
-25,874 Reduced 56.61%
19,835 $472,000
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $125,962 - $201,170
9,228 Added 25.3%
45,709 $899,000
Q3 2018

Nov 09, 2018

BUY
$15.87 - $22.4 $578,953 - $817,174
36,481 New
36,481 $646,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.